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ender-Specific Risk Stratification With B-Type
atriuretic Peptide Levels in Patients With AcuteDyspnea
nsights From the B-type Natriuretic Peptide
or Acute Shortness of Breath Evaluation Study
ichael Christ, MD, Kirsten Laule-Kilian, BSC, Willibald Hochholzer, MD,
heresia Klima, MD, Tobias Breidthardt, MD, Andre P. Perruchoud, MD, Christian Mueller, MD
asel, Switzerland
OBJECTIVES We examined whether B-type natriuretic peptide (BNP) levels allow gender-specific risk
stratification in patients with acute dyspnea.
BACKGROUND B-type natriuretic peptide levels determined in patients with heart failure correlate with the
severity of disease and prognosis. Gender differences in risk prediction are poorly examined.
METHODS The BASEL (B-type natriuretic peptide for Acute Shortness of Breath Evaluation) Study
enrolled 190 female and 262 male patients presenting with acute dyspnea.
RESULTS At 24 months, cumulative mortality was comparable in women and men (38% vs. 35%, p 
0.66). Cox regression analyses revealed that BNP levels 500 pg/ml indicated a 5.1-fold
increase in mortality for women (95% confidence interval [CI] 3.0 to 8.5, p  0.001) versus
a 1.8-fold increase in men (95% CI 1.2 to 2.6; p  0.007). The area under the
receiver-operating characteristic curve (AUC) for BNP to predict death was significantly
higher in female (AUC: 0.80, 95% CI 0.73 to 0.86) than in male patients (AUC: 0.64, 95%
CI 0.57 to 0.71; p  0.001 for the comparison of AUCwomen versus AUCmen). Women with
BNP500 pg/ml displayed a higher mortality as compared with men with BNP500 pg/ml
(68% vs. 46%, p  0.015). Interaction analysis showed that BNP is a stronger predictor of
death in women than in men (p  0.008).
CONCLUSIONS B-type natriuretic peptide plasma levels seem to be stronger predictors of death in women
than in men. (J Am Coll Cardiol 2006;48:1808–12) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.037Cardiology Foundation
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p-type natriuretic peptide (BNP) is an important biomarker
o diagnose heart failure (HF) in patients presenting with
cute dyspnea to the emergency department (1). In this
etting, the use of BNP improves patient management and
s cost-effective (2). B-type natriuretic peptide plasma levels
re not only useful to diagnose HF but also to predict
orbidity and mortality in chronic HF (3).
Important gender differences in HF patients have been
eported (4). Women more likely develop HF after acute
yocardial infarction (5), and women with acute HF have
ess improvement in physical health status during follow-up
nd a lower perceived quality of care than men (6). We
xamined whether BNP plasma levels allow gender-specific
isk stratification in patients with acute dyspnea.
ETHODS
etting and study population. A total of 452 consecutive
atients presenting with acute dyspnea were enrolled in the
ASEL (B-type natriuretic peptide for Acute Shortness of
From the Department of Internal Medicine, Medical Division A, University
ospital, Basel, Switzerland. This study was supported by research grants from the
wiss National Science Foundation (PP00B-102853), the Swiss Heart Foundation,
nd the Novartis Foundation (to Dr. Mueller).e
Manuscript received April 3, 2006; revised manuscript received July 5, 2006,
ccepted July 17, 2006.reath Evaluation) study (2). The study was approved by
he institutional review board and conducted according to
he principles of good clinical practice. Patients with severe
enal disease (serum creatinine250 mol/l) or cardiogenic
hock were excluded.
linical and laboratory assessment. Clinical assessment
ncluding determination of a final discharge diagnosis was
erformed in all patients. B-type natriuretic peptide was
easured with the use of a rapid fluorescence immunoassay
Biosite Inc., San Diego, California) (7). B-type natriuretic
eptide levels were available for the diagnosis in one-half of
resenting patients and determined in a blinded fashion in
he other half of patients (2).
nd points and follow-up. The primary end point of this
nalysis was all-cause mortality related to BNP levels in women
nd men. Each patient was contacted via telephone by a single
rained researcher at specified intervals. If necessary, refer-
ing physicians were contacted regarding a patient’s premor-
id health status, or the administrative databases of respec-
ive hometowns were reviewed.
tatistical analysis. Patients were grouped with prospec-
ively defined and established BNP cutoff points (low:
100 pg/ml; intermediate: 100 to 500 pg/ml; high: 500
g/ml). Cox proportional hazard models were used to
valuate the associations between outcome measures.
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November 7, 2006:1808–12 BNP and Prognosis in Womenvent-free survival was estimated with the Kaplan-Meier
ethod. A receiver-operating characteristic curve was con-
tructed to assess BNP as a predictor of mortality. All p
alues reported are 2-sided, and a p value 0.05 was
onsidered significant. All statistical calculations were per-
ormed with the SPSS statistical software package (version
3.0; SPSS Inc., Chicago, Illinois).
ESULTS
atient characteristics are presented in Table 1. At 24
onths, cumulative mortality was comparable in women
nd men (38% vs. 35%, p  0.66) (Figure 1). In the study
Abbreviations and Acronyms
AUC area under the (receiver-operating characteristic)
curve
BNP  B-type natriuretic peptide
CI  confidence interval
HF  heart failure
able 1. Characteristics of Female and Male Patients Presenting
edical history
History of heart failure
Systemic hypertension 1
Diabetes mellitus
Coronary artery disease
Current smoker
Pulmonary disease
Renal insufficiency
Malignancy
aseline characteristics
Age, yrs
Body mass index, kg/m2
Heart rate, beats/min
Systolic BP, mm Hg
Diastolic BP, mm Hg
Oxygen saturation, %
Breathing rate, beats/min
NYHA functional class
LV ejection fraction, %
Systolic heart failure
Diastolic heart failure
Hemoglobin, g/dl
Leukocytes, 109/l
BNP, pg/ml (median, IQR) 3
inal/discharge diagnosis
Acute heart failure
Coronary artery disease
Nonischemic cardiac disease
Dyspnea unrelated to cardiac causes
Exacerbation of obstructive pulmonary disease
Pneumonia
Pulmonary embolism
Pneumothorax
Anxiety disorder
Other (e.g., cancer, anemia)
Unknownalues expressed as n (%) or mean  SD.
BNP  B-type natriuretic peptide; BP  blood pressure; IQR  interquartile range; Lohort, no significant difference in plasma BNP levels was
bserved between genders (Table 1). However, BNP levels
ere significantly higher in women (median: 835, interquar-
Acute Dyspnea to the Emergency Department
men Men p Value
2) 41 (16) 0.34
3) 136 (52) 0.85
0) 65 (25) 0.26
8) 133 (51) 0.64
8) 75 (29) 0.01
1) 149 (57) 0.001
7) 60 (23) 0.32
9) 51 (19) 1.00
17 69  13 0.07
5.9 26.1  5.3 0.18
25 97  24 0.89
28 145  29 0.80
19 87  18 0.04
6 92  8 0.12
8 24  8 0.84
1 3  1 0.19
14 42  17 0.01
6) 62 (57) 0.14
4) 47 (43) 0.14
2 14  3 0.001
5 11  5 0.56
0–930) 249 (67–878) 0.39
4.7) 87 (33.2) 0.81
4.2) 37 (14.1) 1.00
4.2) 45 (17.2) 0.47
.4) 37 (14.1) 0.06
.7) 12 (4.6) 0.81
) 2 (0.4) 0.23
.2) 8 (3.1) 0.46
3.7) 28 (10.7) 0.24
.8) 6 (2.3) 0.03
igure 1. Survival in 190 female and 262 male patients presenting with
cute dyspnea (log-rank test for comparison of curves).With
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BNP and Prognosis in Women November 7, 2006:1808–12ile range: 440 to 1,300 pg/ml) than in men (median: 459,
nterquartile range: 134 to 1,300 pg/ml; p  0.005) who
ied. Results of univariate Cox regression analyses are
isplayed in Table 2. Cox regression analyses revealed that
isk of death was 5.1-fold higher (95% confidence interval
CI] 3.0 to 8.5, p  0.001) in women with BNP levels
500 pg/ml compared with women with BNP 500
g/ml. Risk of death was 1.8-fold higher in men with BNP
500 pg/ml compared with men with BNP 500 pg/ml
95% CI 1.2 to 2.6; p  0.007). Survival in patients with
NP 500 pg/ml was significantly worse for women than
en (Figure 2). The area under the receiver-operating
haracteristic curve (AUC) for BNP to predict death was
ignificantly greater for women than men (p  0.001)
Figure 3).
B-type natriuretic peptide levels, in addition to body mass
ndex and age, significantly contributed to multivariate Cox
egression models indicating increased risk of death in
omen (Table 3). B-type natriuretic peptide plasma levels
id not independently predict death in men. Interaction
nalysis showed that risk prediction with BNP is dependent
n gender and BNP is a stronger predictor of risk of death
n women than in men (p  0.008). The BNP levels were
eakly associated with age (r2  0.06 for women, p 
.001; r2  0.02 for men, p  0.07). In addition, negative
inear associations with body mass index (r2  0.09 for
able 2. Univariate Cox Proportional Hazard Analyses in Female
Variable
Women
Mortality Point Estimate (95% C
aseline characteristics
Age, yrs 1.07 (1.05–1.10)
Body mass index, kg/m2 0.90 (0.85–0.94)
Systolic BP, mm Hg 0.99 (0.99–1.00)
Heart rate, beats/min 1.01 (0.99–1.02)
Oxygen saturation, % 0.97 (0.94–1.01)
Breathing rate, beats/min 1.04 (0.99–1.08)
NYHA functional class 1.25 (0.91–1.72)
edical history
Systemic hypertension 1.00 (0.64–1.58)
Diabetes mellitus 1.02 (0.59–1.78)
Coronary artery disease 2.83 (1.74–4.60)
Current smoking 0.64 (0.33–1.24)
Pulmonary disease 1.00 (0.63–1.58)
Malignancy 1.60 (0.96–2.68)
edication at presentation
Diuretics 2.66 (1.66–4.27)
ACE inhibitors/ARB 1.47 (0.93–2.32)
Beta-blockers 1.01 (0.59–1.74)
aboratory parameters
Hemoglobin, g/dl 0.89 (0.81–0.98)
Leukocytes, 109/l 1.04 (0.99–1.09)
Troponin I 2.0 ug/l 1.69 (1.01–2.84)
BNP, pg/ml 1.001 (1.001–1.002)
BNP classes 3.38 (2.30–4.98)
Creatinine clearance, ml/min 0.98 (0.98–0.99)
CE  angiotensin-converting enzyme; ARB  angiotensin II type 1 receptor blocomen, p  0.001; r2  0.1 for men, p  0.001) and renal
F
(unction (r2  0.21 for women, p  0.001; r2  0.20 for
en, p  0.001) were found.
Resource use (p  0.81 for hospital stay; p  0.27 for
ransfer to intensive care unit) and discharge medication was
omparable in women and men. Echocardiography was
erformed in 48% of women and 51% of men (p 0.57). At
ischarge, angiotensin-converting enzyme (ACE) inhibitors
p  0.55) and beta-blockers (p  0.92) were prescribed
imilarly for women and men. An exploratory analysis
Male Patients Presenting With Acute Dyspnea
Men
p Value Mortality Point Estimate (95% CI) p Value
0.001 1.04 (1.02–1.06) 0.001
0.001 0.96 (0.92–1.01) 0.07
0.16 0.99 (0.98–0.99) 0.03
0.10 1.01 (0.99–1.02) 0.09
0.12 0.97 (0.95–0.99) 0.001
0.07 1.00 (0.97–1.04) 0.97
0.16 1.52 (1.09–2.11) 0.02
0.99 1.44 (0.96–2.16) 0.08
0.93 1.16 (0.74–1.81) 0.52
0.001 2.03 (1.34–3.09) 0.001
0.19 1.20 (0.79–1.84) 0.40
0.99 1.68 (1.10–2.56) 0.02
0.07 2.17 (1.41–3.36) 0.001
0.001 1.91 (1.26–2.89) 0.002
0.10 1.01 (0.68–1.51) 0.96
0.97 0.86 (0.53–1.37) 0.52
0.02 0.85 (0.78–0.92) 0.001
0.11 1.00 (0.99–1.01) 0.83
0.04 1.70 (0.99–2.92) 0.05
0.001 1.001 (1.000–1.001) 0.001
0.001 1.49 (1.15–1.93) 0.002
0.004 0.98 (0.98–0.99) 0.003
I  confidence interval; other abbreviations as in Table 1.and
I)igure 2. Survival in women and men with B-type natriuretic peptide
BNP) levels 500 pg/ml (log-rank test for comparison of curves).
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November 7, 2006:1808–12 BNP and Prognosis in Womenhowed that gender-differences in risk prediction are par-
icularly evident in patients with cardiac dyspnea (Figure 4).
ISCUSSION
he present study examined whether increased BNP plasma
evels are equally useful in the risk stratification of women
nd men presenting with acute dyspnea to the emergency
epartment. The main results are the following: 1) patients
resenting with acute dyspnea displayed a high mortality
ate independent of gender, 2) women with BNP levels
500 pg/ml had significantly higher mortality than men
ith BNP levels 500 pg/ml, 3) BNP levels were signifi-
ant independent predictors of death in women but not in
en, and 4) receiver operating characteristics and interac-
ion analysis confirmed that BNP levels were stronger
redictors of death in women than in men.
Elevated BNP levels in patients with acute dyspnea
ndicate poor prognosis, thus extending data obtained in
atients with chronic (3) or acute HF after 6 months of
ollow-up (8). Previous data suggest that levels of natriuretic
eptides in women are in excess of that in men with
omparable symptom and disease severity. Subsequently, it
as been suggested to use higher BNP cutoff levels for the
igure 3. Receiver-operating characteristic curves analyzing the ability of
-type natriuretic peptide (BNP) levels to predict death in women and
en. Area under the receiver operating characteristics curve (AUC) with
5% confidence intervals (CI) are given.
able 3. Multivariable Cox Proportional Hazard Analyses for
he Prediction of Death in Female and Male Patients
Variable
Point Estimate
(95% CI)
p
Value
emale patients
BNP classes 2.58 (1.64–4.05) 0.001
Age, yrs 1.04 (1.02–1.07) 0.002
Body mass index, kg/m2 0.93 (0.87–0.99) 0.02
ale patients
Taking diuretics at presentation 2.72 (1.61–4.62) 0.001
Presence of any malignancy 2.50 (1.44–4.33) 0.001
Presence of any pulmonary disease 2.32 (1.9–3.88) 0.001
Systolic blood pressure, mm Hg 0.99 (0.98–0.99) 0.01
Troponin I 2.0 g/l 1.78 (1.03–3.05) 0.04C
NP  B-type natriuretic peptide; CI  confidence interval.iagnosis and management of HF in women (9). Our
ndings in patients presenting with acute dyspnea demon-
trate that increased BNP levels are associated with an
xcess risk of death to a greater extent in women than in
en. Possibly owing to the high prevalence of diastolic HF,
F severity might be underestimated by noninvasive diag-
ostic tests in women. This could potentially lead to
nderuse of appropriate HF treatment (10).
Our data suggest that BNP might be a more appropriate
est to estimate severity of cardiac disease in women,
hereas other diagnostic measures might be more useful for
isk prediction in men. It is tempting to speculate whether
NP formation and release might be regulated gender-
pecifically. Indeed, sex hormones interact with regulation
f neurohormones including natriuretic peptides (11).
tudy limitations. First, we prospectively decided to
ecord all-cause mortality because classification of death in
linical practice is inaccurate, challenging, and might lead to
uestionable conclusions. However, detailed information
egarding causes of death might have provided additional
nsights. Second, this is a post hoc analysis of a moderate-
ized randomized controlled study. Therefore, our findings
eed to be confirmed by additional studies before definite
onclusions regarding gender-specific risk prediction in
eneral and optimal cutoff values in particular can be made.
onclusions. Patients presenting with acute dyspnea to
he emergency department display poor particular prognosis
ndependent of gender. B-type natriuretic peptide plasma
evels seem to be stronger predictors of death in women than
n men.
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